Alex Sapir, Fulcrum Therapeutics CEO
July 10, 2023 10:45 AM EDTUpdated 11:12 AM
Deals

Ful­crum inks dis­cov­ery deal with Camp4 Ther­a­peu­tics

Paul Schloesser

Associate Editor

With a new CEO at the helm and its hema­to­log­i­cal pro­gram still un­der a clin­i­cal hold, Ful­crum Ther­a­peu­tics has signed a li­cens­ing and dis­cov­ery deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times